Survival Analysis of 148 Patients with Primary Diffuse Large B Cell Lymphoma.
10.7534/j.issn.1009-2137.2019.01.010
- Author:
Ya-Ru XU
1
;
Li LIU
1
;
Xiu-Hong REN
1
;
Ping-Ping LIU
1
;
Hao ZHANG
1
;
Li ZHENG
1
;
Song-Song ZHANG
1
;
Li-Qiang ZHOU
2
,
3
;
Zhen-Xing GUO
4
Author Information
1. Department of Hematology/Oncology，The First Hospital of Tsinghua University，Beijing 100016，China.
2. Department of Medical Oncology，Cancer Hospital of Chinese Academy of Medical Sciences，Beijing 100021，China.E-mail:zhouliqiang_bj@
3. com.
4. Department of Hematology/Oncology，The First Hospital of Tsinghua University，Beijing 100016，China.E-mail: gzx2962@outlook.com.
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal, Murine-Derived;
Antineoplastic Combined Chemotherapy Protocols;
Cyclophosphamide;
Disease-Free Survival;
Doxorubicin;
Humans;
Lymphoma, Large B-Cell, Diffuse;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2019;27(1):61-66
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical outcome of the patients with primary diffuse large B-cell lymphoma（DLBCL）.
METHODS:Clinical data of 148 patients with DLBCL in our hospital and cancer hospital from March 2006 to April 2016 were retrospectively analyzed. Kaplan-Meier analysis was used to estimate progression-free survival（PFS）and overall survival（OS）.
RESULTS:5-year OS and PFS rates were 85% and 69%，respectively. The survival analysis showed that 5-year OS rate of R-CHOP group was significantly higher than that of CHOP alone group（89% vs. 70%，P<0.05）. In univariate analysis，several clinical factors，such as older age（>60 years），poor ECOG score（≥2），advanced stage（Ⅲ-Ⅳ），higher IPI score（≥3），CHOP alone and absence of radiotherapy related with poor survival rate. Furthermore，multivariate analysis showed that age>60 year significantly related with the worse OS.
CONCLUSION:Age >60 year is an important independent prognostic factor to predict worse OS or PFS.
